NCT01413178 · OUTCOME

Treatment-Related Mortality (TRM) Between 2 Arms.

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma · Source last updated 2020-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 100 days post treatment

Groups in this outcome

Busulfan + Melphalan

Busulfan with a target daily area under the curve (AUC) of 5000 with Melphalan 70 mg/m2 followed by a stem cell transplant

Melphalan

High-dose Melphalan 200 mg/m2/day followed by a stem cell transplant

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Busulfan + Melphalan	104
Melphalan	98

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Busulfan + Melphalan	0	Not reported	Not reported	Not reported	Not reported
Melphalan	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0

denoms

counts
group Id
OG000
value
104
group Id
OG001
value
98
units
Participants

groups

description
Busulfan with a target daily area under the curve (AUC) of 5000 with Melphalan 70 mg/m2 followed by a stem cell transplant
id
OG000
title
Busulfan + Melphalan
description
High-dose Melphalan 200 mg/m2/day followed by a stem cell transplant
id
OG001
title
Melphalan

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

100 days post treatment

title

Treatment-Related Mortality (TRM) Between 2 Arms.

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice